Icon Plc $ICLR Shares Bought by Canoe Financial LP

Canoe Financial LP raised its holdings in Icon Plc (NASDAQ:ICLR) by 2.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 197,970 shares of the medical research company’s stock after purchasing an additional 4,119 shares during the quarter. Canoe Financial LP’s holdings in Icon were worth $34,645,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of ICLR. SVB Wealth LLC acquired a new stake in shares of Icon during the 1st quarter worth about $28,000. Pinnacle Wealth Planning Services Inc. boosted its stake in Icon by 8.7% during the first quarter. Pinnacle Wealth Planning Services Inc. now owns 1,657 shares of the medical research company’s stock worth $290,000 after buying an additional 132 shares during the period. First National Bank Sioux Falls increased its position in shares of Icon by 5.7% during the second quarter. First National Bank Sioux Falls now owns 1,580 shares of the medical research company’s stock valued at $230,000 after acquiring an additional 85 shares during the last quarter. Confluence Investment Management LLC increased its position in shares of Icon by 5.9% during the second quarter. Confluence Investment Management LLC now owns 4,132 shares of the medical research company’s stock valued at $601,000 after acquiring an additional 232 shares during the last quarter. Finally, Greenhaven Associates Inc. purchased a new stake in shares of Icon in the 2nd quarter valued at approximately $2,565,000. 95.61% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. UBS Group set a $220.00 price objective on shares of Icon in a research report on Friday, October 24th. TD Cowen decreased their price target on Icon from $183.00 to $172.00 and set a “hold” rating on the stock in a research note on Friday, October 24th. Barclays raised their price target on Icon from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Monday, December 15th. Robert W. Baird set a $220.00 target price on Icon in a research note on Friday, October 24th. Finally, BMO Capital Markets began coverage on Icon in a report on Thursday, November 13th. They set a “market perform” rating and a $175.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and eleven have assigned a Hold rating to the stock. According to MarketBeat.com, Icon currently has a consensus rating of “Moderate Buy” and an average target price of $205.31.

Icon Trading Up 0.3%

ICLR opened at $183.64 on Friday. The business has a fifty day moving average price of $175.41 and a 200 day moving average price of $169.41. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06. Icon Plc has a 12 month low of $125.10 and a 12 month high of $228.29. The stock has a market capitalization of $14.83 billion, a price-to-earnings ratio of 24.85, a PEG ratio of 3.40 and a beta of 1.25.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.